Mutual mistrust: FDA staff wary as Høeg becomes top drug regulator
Tracy Beth Høeg, a former resident physician and ultramarathon runner, has come a long way since expressing her dismay at Sarah Palin’s denial of climate change back in 2008. Now, as the acting director of the FDA’s Center for Drug Evaluation and Research, Høeg finds herself facing accusations of bias from FDA staff.
Høeg’s journey to this role has been a tumultuous one. After serving as the scientific adviser to FDA Commissioner Marty Makary for nine months, concerns have been raised about her ability to oversee drug regulation without bias. This is a critical aspect of her new position, where impartially reviewing scientific evidence about the benefits and risks of medical treatments is essential.
Despite the controversy surrounding her appointment, Høeg’s bosses and former colleagues believe she is capable of fulfilling the responsibilities of her new role. However, doubts remain about her ability to make decisions based on scientific evidence rather than personal beliefs.
As Høeg steps into her new position on Monday, the spotlight will be on her as she navigates the challenging terrain of drug regulation. It remains to be seen how she will handle the pressure and scrutiny that comes with such a crucial role in safeguarding public health.
